Article
Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Apr 2017
Remon J, Caramella C, Jovelet C, Lacroix L, Lawson A, Smalley S, Howarth K, Gale D, Green E, Plagnol V, Rosenfeld N, Planchard D, Bluthgen M V, Gazzah A, Pannet C, Nicotra C, Auclin E, Soria J C, Besse B
Abstract excerpt
Background: Approximately 50% of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitors (TKIs) will acquire resistance by the T790M mutation. Osimertinib is the standard of care in this situation. The present study assesses the efficacy of osimertinib when T790M status is determined in circulating cell-free tumour DNA (ctDNA) from...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.